Efficacy of paracetamol on patent ductus arteriosus closure may be dose dependent: Evidence from human and murine studies

Pediatric Research

Volumn 76, Issue 3, 2014, Pages 238-244

  El Khuffash, Afif ^a   Jain, Amish ^b   Corcoran, David ^a   Shah, Prakesh S ^b   Hooper, Christopher W ^c   Brown, Naoko ^c   Poole, Stanley D ^c   Shelton, Elaine L ^c   Milne, Ginger L ^d   Reese, Jeff ^c   McNamara, Patrick J ^e  

^a ROTUNDA HOSPITAL   (Ireland)

^b MOUNT SINAI HOSPITAL   (Canada)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; PARACETAMOL; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; VASOCONSTRICTOR AGENT;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEMODYNAMICS; HUMAN; IN VITRO STUDY; INFANT; MOUSE; MYOGRAPHY; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PREMATURITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RETROSPECTIVE STUDY; TREATMENT DURATION; ANIMAL; BLOOD PRESSURE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; DUCTUS ARTERIOSUS; DUCTUS ARTERIOSUS, PATENT; INTRAVENOUS DRUG ADMINISTRATION; LIGATION; METABOLISM; NEWBORN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; VASOCONSTRICTION;

ACETAMINOPHEN; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DUCTUS ARTERIOSUS; DUCTUS ARTERIOSUS, PATENT; HUMANS; INDOMETHACIN; INFANT, NEWBORN; LIGATION; PROSTAGLANDIN ANTAGONISTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84907324541     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2014.82     Document Type: Article

References (25)

1. Clyman RI, Couto J, Murphy GM. Patent ductus arteriosus: are current neonatal treatment options better or worse than no treatment at all? Semin Perinatol 2012;36:123-9.
2. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D. Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics 2011;128:e1618-21.
3. Oncel MY, Yurttutan S, Degirmencioglu H, et al. Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology 2013;103:166-9.
4. Oncel MY, Yurttutan S, Uras N, et al. An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed 2013;98:F94.
5. Tekgunduz KS, Ceviz N, Demirelli Y, et al. Intravenous paracetamol for patent ductus arteriosus in premature infants - a lower dose is also effective. Concerning the article by M.Y. Oncel et al: Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology 2013;104:6-7.
6. Yurttutan S, Oncel MY, Arayic S, et al. A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med 2013;26:825-7.
7. Allegaert K, Anderson B, Simons S, van Overmeire B. Paracetamol to induce ductus arteriosus closure: is it valid? Arch Dis Child 2013;98:462-6.
8. Ozdemir OM, Doan M, Küçüktaç K, Ergin H, Sahin O. Paracetamol therapy for patent ductus arteriosus in premature infants: a chance before surgical ligation. Pediatr Cardiol 2014;35:276-9.
9. Roofthooft DW, van Beynum IM, Helbing WA, Reiss IK, Simons SH. Paracetamol for ductus arteriosus closure: not always a success story. Concerning the article by M.Y. Oncel et al: intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology 2013;104:170.
10. Alan S, Kahvecioglu D, Erdeve O, Atasay B, Arsan S. Is paracetamol a useful treatment for ibuprofen-resistant patent ductus arteriosus? Concerning the article by M.Y. Oncel et al: intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology 2013;104:168-9.
11. Reese J, O'Mara PW, Poole SD, et al. Regulation of the fetal mouse ductus arteriosus is dependent on interaction of nitric oxide and COX enzymes in the ductal wall. Prostaglandins Other Lipid Mediat 2009;88:89-96.
12. Oncel MY, Yurttutan S, Erdeve O, et al. Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants: a randomized controlled trial. J Pediatr 2014;164:510-4.e1.
13. Moise KJ Jr. Effect of advancing gestational age on the frequency of fetal ductal constriction in association with maternal indomethacin use. Am J Obstet Gynecol 1993;168:1350-3.
14. Vermillion ST, Scardo JA, Lashus AG, Wiles HB. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997;177:256-9; discussion 259-61.
15. Momma K, Toyono M. The role of nitric oxide in dilating the fetal ductus arteriosus in rats. Pediatr Res 1999;46:311-5.
16. Momma K, Takao A. Transplacental cardiovascular effects of four popular analgesics in rats. Am J Obstet Gynecol 1990;162:1304-10.
17. Bouayad A, Bernier SG, Asselin P, et al. Characterization of PGE2 receptors in fetal and newborn ductus arteriosus in the pig. Semin Perinatol 2001;25:70-5.
18. Guerguerian AM, Hardy P, Bhattacharya M, et al. Expression of cyclooxygenases in ductus arteriosus of fetal and newborn pigs. Am J Obstet Gynecol 1998;179(6 Pt 1):1618-26.
19. Ali I, Ryan CA. Transient renal failure in twins with maternal Cox-1/Cox-2 use in pregnancy. Ir Med J 2005;98:249-50.
20. King J, Flenady V, Cole S, Thornton S. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2005;2: CD001992.
21. El-Khuffash AF, McNamara PJ. Neonatologist-performed functional echocardiography in the neonatal intensive care unit. Semin Fetal Neonatal Med 2011;16:50-60.
22. Liu T, Laidlaw TM, Feng C, et al. Prostaglandin E2 deficiency uncovers a dominant role for thromboxane A2 in house dust mite-induced allergic pulmonary inflammation. Proc Natl Acad Sci USA 2012;109:12692-7.
23. Morrow JD, Roberts LJ 2nd. Mass spectrometric quantification of F2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol 1999;300:3-12.
24. Murali G, Milne GL, Webb CD, et al. Fish oil and indomethacin in combination potently reduce dyslipidemia and hepatic steatosis in LDLR(-/-) mice. J Lipid Res 2012;53:2186-97.
25. Hoggatt J, Mohammad KS, Singh P, et al. Differential stem- and progenitorcell trafficking by prostaglandin E2. Nature 2013;495:365-9.